

## ROCTAVIAN (valoctocogene roxaparvovec-rvox)

Member and Medication Information	
* indicates required field	
*Member ID:	*Member Name:
*DOB:	*Weight:
*Medication Name/Strength:	<input type="checkbox"/> Do Not Substitute. Authorizations will be processed for the preferred Generic/Brand equivalent unless specified.
*Directions for use:	
Provider Information	
* indicates required field	
*Requesting Provider Name:	*NPI:
*Address:	
*Contact Person:	*Phone #:
*Fax #:	Email:
Medically Billed Information	
* indicates required field for all medically billed products	
*Diagnosis Code:	*HCPCS Code:
*Dosing Frequency:	*HCPCS Units per dose:
Servicing Provider Name:	NPI:
Servicing Provider Address:	
Facility/Clinic Name:	NPI:
Facility/Clinic Address:	
Fax form and relevant documentation including: laboratory results, chart notes and/or updated provider letter to Pharmacy PA at <b>855-828-4992</b> , to prevent processing delays.	

**Criteria for Approval:** *(all the following criteria must be met)*

- Prescribed by a hematologist, specializing in the care of patients with hemophilia A
- Patient is 18 years of age or older
- Patient has not received Roctavian or any other gene therapy before
- Patient has the diagnosis of severe hemophilia A (congenital Factor VIII (FVIII) deficiency with FVIII activity < 1 IU/dL)
- Patient does not have antibodies to adeno-associated virus serotype 5 (AAV5) as detected by an FDA-approved test.
- Patient has no previous documented history of detectable factor VIII inhibitor
- Prescriber **attests** to these following assessments prior to administer Roctavian:
  - o Obtaining and evaluating liver function tests
  - o Assessing the patient’s ability to receive corticosteroids and / or other immunosuppressive therapy that maybe required for an extended period
  - o That the patient **does not** have active infections, either acute or uncontrolled chronic infections.
  - o That patient **does not** have any known significant hepatic fibrosis (stage 3 or 4 on the Batts-Ludwig scale or equivalent) or cirrhosis, or mannitol hypersensitivity.

**Initial Authorization:** One (1) dose per lifetime

**Re-authorization Criteria:** None

# UTAH MEDICAID PHARMACY PRIOR AUTHORIZATION REQUEST FORM

**Note:**

- ❖ Use appropriate HCPCS codes for billing
- ❖ Coverage and Reimbursement code look up: <https://health.utah.gov/stplan/lookup/CoverageLookup.php>
- ❖ HCPCS NDC Crosswalk: <https://health.utah.gov/stplan/lookup/FeeScheduleDownload.php>

**PROVIDER CERTIFICATION**

I hereby certify this treatment is indicated, necessary and meets the guidelines for use.

\_\_\_\_\_  
Prescriber's Signature

\_\_\_\_\_  
Date